Q-omics provides the consensus-scored GOLGA8O profile across patient tissues and cancer cell-line models. GOLGA8O expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GOLGA8O is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, GOLGA8O RNA expression shows 15,221 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, THCA, and THYM as cancer lineages where GOLGA8O shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA8O — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA8O survival associations across molecular data types. GOLGA8O RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA8O RNA expression–survival associations across cancer types. High GOLGA8O expression shows unfavorable associations in LGG and COAD, but favorable associations in MESO, PAAD, LIHC and ACC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for GOLGA8O RNA expression.
This table summarizes GOLGA8O tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA8O. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA8O shows lower tumor expression in THCA, BRCA, LUSC and LUAD and higher tumor expression in HNSC and KIRC. The THCA box plot shows higher GOLGA8O RNA expression in normal versus tumor tissue (log2 FC = −0.733, t-test p < 0.001).
This table shows molecular features associated with GOLGA8O in patient tissues and cancer cell lines. In patient samples, GOLGA8O shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA8O RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
